418 related articles for article (PubMed ID: 28273381)
1. Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence.
Yim J; Smith JR; Rybak MJ
Pharmacotherapy; 2017 May; 37(5):579-592. PubMed ID: 28273381
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options for infections due to vancomycin-resistant enterococci.
Wang JL; Hsueh PR
Expert Opin Pharmacother; 2009 Apr; 10(5):785-96. PubMed ID: 19351228
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.
Summers M; Misenhimer GR; Antony SJ
South Med J; 2001 Mar; 94(3):353-5. PubMed ID: 11284529
[TBL] [Abstract][Full Text] [Related]
6. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children.
Tamma PD; Hsu AJ
Curr Opin Infect Dis; 2014 Dec; 27(6):517-27. PubMed ID: 25313503
[TBL] [Abstract][Full Text] [Related]
7. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium.
Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW
Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685
[TBL] [Abstract][Full Text] [Related]
8. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci.
Messick CR; Pendland SL
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):203-5. PubMed ID: 9401814
[TBL] [Abstract][Full Text] [Related]
10. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin.
Shrestha NK; Chua JD; Tuohy MJ; Wilson DA; Procop GW; Longworth DL; Isada CM; Hall GS
Scand J Infect Dis; 2003; 35(1):12-4. PubMed ID: 12685877
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin-resistant enterococcal urinary tract infections.
Heintz BH; Halilovic J; Christensen CL
Pharmacotherapy; 2010 Nov; 30(11):1136-49. PubMed ID: 20973687
[TBL] [Abstract][Full Text] [Related]
13. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents.
Hsueh PR; Chen WH; Teng LJ; Luh KT
Int J Antimicrob Agents; 2005 Jul; 26(1):43-9. PubMed ID: 15975769
[TBL] [Abstract][Full Text] [Related]
14. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates.
Tang HJ; Chen CC; Zhang CC; Su BA; Li CM; Weng TC; Chiang SR; Ko WC; Chuang YC
Diagn Microbiol Infect Dis; 2013 Nov; 77(3):254-7. PubMed ID: 24029433
[TBL] [Abstract][Full Text] [Related]
15. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China.
Wang S; Guo Y; Lv J; Qi X; Li D; Chen Z; Zhang X; Wang L; Yu F
BMC Microbiol; 2016 Oct; 16(1):246. PubMed ID: 27769188
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin).
McNeil SA; Clark NM; Chandrasekar PH; Kauffman CA
Clin Infect Dis; 2000 Feb; 30(2):403-4. PubMed ID: 10671355
[No Abstract] [Full Text] [Related]
17. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
[TBL] [Abstract][Full Text] [Related]
18. Emergence and management of drug-resistant enterococcal infections.
Arias CA; Murray BE
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):637-55. PubMed ID: 18847403
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy.
Shea K; Hilburger E; Baroco A; Oldfield E
Ann Pharmacother; 2008 May; 42(5):722-5. PubMed ID: 18349306
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
[Next] [New Search]
